by Philippa Shelton | Feb 2025 | Blogs, VHH Resources, VHHs
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics Updated on Feb. 16th, 2025 – Since their discovery over thirty years ago, monoclonal antibodies (mAbs) based on Immunoglobulin G (IgG) have...
by Isogenica Webmaster | Jan 2025 | Blogs
Challenging assumptions in antigen QC for antibody discovery success Not all projects go as planned, but breakthroughs often emerge from the most unexpected challenges. This case study explores how a technical obstacle during early QC could have derailed a VHH...
by Isogenica Webmaster | Nov 2024 | Blogs
Synthetic Biology Technologies for Antibody Discovery Imagine bypassing the lengthy traditional immunization process and tapping into the antibody diversity equivalent of over a million llamas – right at your fingertips. At Isogenica, our libraries, built with...
by Isogenica Webmaster | Oct 2024 | Blogs
Your Expert in Nanobodies Antibody Discovery Nanobody is widely used to describe single-domain antibodies, but VHH is the accurate term for the isolated variable domain found in camelid heavy-chain-only antibodies. Discover the Power of VHH's Nanobody or VHH...
by Isogenica Webmaster | Sep 2024 | Blogs, Case studies
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles In the fast-paced world of biotechnology, innovation often stems from taking smart, calculated risks. At Isogenica, we are used to running unusual antibody drug discovery...
by Isogenica Webmaster | Sep 2024 | Blogs
Specific Antibodies to Difficult Targets: How to find the needles in the haystack Peptides, often small and unstructured, are some of the most difficult targets in antibody discovery. Here, we recount how we tweaked our approach to mining our vast VHH libraries to...
